<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Oral Cancer News &#187; survival</title>
	<atom:link href="http://oralcancernews.org/wp/tag/survival/feed/" rel="self" type="application/rss+xml" />
	<link>http://oralcancernews.org/wp</link>
	<description>The Oral Cancer Foundation News Archive</description>
	<lastBuildDate>Mon, 21 May 2012 12:57:26 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>Taiwan reports highest oral cancer survivor rate</title>
		<link>http://oralcancernews.org/wp/taiwan-reports-highest-oral-cancer-survivor-rate/</link>
		<comments>http://oralcancernews.org/wp/taiwan-reports-highest-oral-cancer-survivor-rate/#comments</comments>
		<pubDate>Wed, 07 Mar 2012 22:33:15 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[five year]]></category>
		<category><![CDATA[stage four]]></category>
		<category><![CDATA[survival]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12605</guid>
		<description><![CDATA[Source: www.chinapost.com.tw/ Taiwan has reported the highest five-year survival rate for patients with oral cancer in the world, a hospital official said yesterday. On average, more than 70 percent of the oral cancer patients treated at National Taiwan University Hospital (NTUH) live for more than five years after being diagnosed, said Ko Jeng-yuh, head of [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/taiwan-reports-highest-oral-cancer-survivor-rate/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>UT MD Anderson article offers one roadmap for defining value in health care, earns national award from leading journal</title>
		<link>http://oralcancernews.org/wp/ut-md-anderson-article-offers-one-roadmap-for-defining-value-in-health-care-earns-national-award-from-leading-journal/</link>
		<comments>http://oralcancernews.org/wp/ut-md-anderson-article-offers-one-roadmap-for-defining-value-in-health-care-earns-national-award-from-leading-journal/#comments</comments>
		<pubDate>Sat, 04 Feb 2012 02:56:16 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[costs]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[patient outcomes]]></category>
		<category><![CDATA[survival]]></category>
		<category><![CDATA[value proposition]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12422</guid>
		<description><![CDATA[Source: http://www.newswise.com Author: University of Texas M. D. Anderson Cancer Center A team from The University of Texas MD Anderson Cancer Center is receiving a national award for a research article tackling a question vital to the future of health care with reform regulations looming, competition growing and costs rising. The MD Anderson study took [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/ut-md-anderson-article-offers-one-roadmap-for-defining-value-in-health-care-earns-national-award-from-leading-journal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>GP96 is over-expressed in oral cavity cancer and is a poor prognostic indicator for patients receiving radiotherapy</title>
		<link>http://oralcancernews.org/wp/gp96-is-over-expressed-in-oral-cavity-cancer-and-is-a-poor-prognostic-indicator-for-patients-receiving-radiotherapy/</link>
		<comments>http://oralcancernews.org/wp/gp96-is-over-expressed-in-oral-cavity-cancer-and-is-a-poor-prognostic-indicator-for-patients-receiving-radiotherapy/#comments</comments>
		<pubDate>Sat, 15 Oct 2011 13:06:51 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[GP96]]></category>
		<category><![CDATA[locoregional]]></category>
		<category><![CDATA[metastasis]]></category>
		<category><![CDATA[radioresistance]]></category>
		<category><![CDATA[radiotherapy]]></category>
		<category><![CDATA[survival]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=11927</guid>
		<description><![CDATA[Source: http://7thspace.com Author: Chien-Yu Lin et al. Oral cavity cancers (ORC) are the most common cancers, and standard treatment is radical surgery with postoperative radiotherapy. However, locoregional failure remains a major problem, indicating radioresistance an important issue. Our previous work has shown that GP96 contributed to radioresistance in nasopharyngeal and oral cancer cell lines. In [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/gp96-is-over-expressed-in-oral-cavity-cancer-and-is-a-poor-prognostic-indicator-for-patients-receiving-radiotherapy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>What accounts for racial differences in head/neck cancer?</title>
		<link>http://oralcancernews.org/wp/what-accounts-for-racial-differences-in-headneck-cancer/</link>
		<comments>http://oralcancernews.org/wp/what-accounts-for-racial-differences-in-headneck-cancer/#comments</comments>
		<pubDate>Tue, 20 Sep 2011 02:21:47 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[African-Americans]]></category>
		<category><![CDATA[kinase inhibitor]]></category>
		<category><![CDATA[quality of life]]></category>
		<category><![CDATA[racial differences]]></category>
		<category><![CDATA[radiation therapy]]></category>
		<category><![CDATA[smokers]]></category>
		<category><![CDATA[surgery]]></category>
		<category><![CDATA[survival]]></category>
		<category><![CDATA[survival rate]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=11800</guid>
		<description><![CDATA[Source: www.drbicuspid.com Author: DrBicuspid Staff Why are African-Americans more likely than Caucasians not only to be diagnosed with head and neck cancer, but also to die from the disease? While the answer isn&#8217;t a simple one, differences in lifestyle, access to care, and tumor genetics may be partly to blame, according to a new study [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/what-accounts-for-racial-differences-in-headneck-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Sanford researcher to study new oral cancer therapy</title>
		<link>http://oralcancernews.org/wp/sanford-researcher-to-study-new-oral-cancer-therapy/</link>
		<comments>http://oralcancernews.org/wp/sanford-researcher-to-study-new-oral-cancer-therapy/#comments</comments>
		<pubDate>Sat, 16 Jul 2011 18:48:35 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[DCA]]></category>
		<category><![CDATA[dichloroacetate]]></category>
		<category><![CDATA[Food and Drug Administration]]></category>
		<category><![CDATA[HPV]]></category>
		<category><![CDATA[human papilloma virus]]></category>
		<category><![CDATA[immune system]]></category>
		<category><![CDATA[PDK]]></category>
		<category><![CDATA[pyruvate dehydrogenase kinase]]></category>
		<category><![CDATA[radiation]]></category>
		<category><![CDATA[survival]]></category>
		<category><![CDATA[toxicities]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=11447</guid>
		<description><![CDATA[Source: www.mdnews.com Author: public release A new Sanford clinical trial will study the safety and effectiveness of a drug treatment on patients receiving radiation and chemotherapy for head and neck cancer. About three to five percent of all cancers reported in the United States are head and neck cancers. Although the incidence of this type [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/sanford-researcher-to-study-new-oral-cancer-therapy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Polymeric nanoparticles attack head and neck cancer</title>
		<link>http://oralcancernews.org/wp/polymeric-nanoparticles-attack-head-and-neck-cancer/</link>
		<comments>http://oralcancernews.org/wp/polymeric-nanoparticles-attack-head-and-neck-cancer/#comments</comments>
		<pubDate>Sat, 16 Jul 2011 18:43:31 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[dendrimer]]></category>
		<category><![CDATA[Folic Acid]]></category>
		<category><![CDATA[methotrexate]]></category>
		<category><![CDATA[nanoparticle]]></category>
		<category><![CDATA[survival]]></category>
		<category><![CDATA[tumor-targeted]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=11443</guid>
		<description><![CDATA[Source: www.nanowerk.com Author: staff Head and neck cancer, the sixth most common cancer in the world, has remained one of the more difficult malignancies to treat, and even when treatment is successful, patients suffer severely from the available therapies. Now, researchers at the University of Michigan have developed a tumor-targeted nanoparticle that delivers high doses [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/polymeric-nanoparticles-attack-head-and-neck-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Increasing incidence of oral tongue squamous cell carcinoma in young white women, age 18 to 44 years</title>
		<link>http://oralcancernews.org/wp/increasing-incidence-of-oral-tongue-squamous-cell-carcinoma-in-young-white-women-age-18-to-44-years/</link>
		<comments>http://oralcancernews.org/wp/increasing-incidence-of-oral-tongue-squamous-cell-carcinoma-in-young-white-women-age-18-to-44-years/#comments</comments>
		<pubDate>Sat, 12 Mar 2011 19:59:26 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[cancer patient population]]></category>
		<category><![CDATA[incidence]]></category>
		<category><![CDATA[survival]]></category>
		<category><![CDATA[young white women]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=10662</guid>
		<description><![CDATA[Source: jco.ascopubs.org Authors: Sagar C. Patel et al. Purpose: To evaluate the incidence of oral cavity squamous cell carcinoma (OCSCC) and oral tongue squamous cell carcinoma (OTSCC) in young white women, age 18 to 44 years. Patients and Methods: We analyzed incidence and survival data from the Surveillance, Epidemiology and End Results (SEER) Program of [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/increasing-incidence-of-oral-tongue-squamous-cell-carcinoma-in-young-white-women-age-18-to-44-years/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>In cancer survival, &#8216;mind matters,&#8217; says expert</title>
		<link>http://oralcancernews.org/wp/in-cancer-survival-mind-matters-says-expert/</link>
		<comments>http://oralcancernews.org/wp/in-cancer-survival-mind-matters-says-expert/#comments</comments>
		<pubDate>Sun, 06 Feb 2011 16:15:28 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[depression]]></category>
		<category><![CDATA[end of life]]></category>
		<category><![CDATA[palliative care]]></category>
		<category><![CDATA[psychologic/psychiatric interventions]]></category>
		<category><![CDATA[psychosocial interventions]]></category>
		<category><![CDATA[survival]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=10448</guid>
		<description><![CDATA[Source: www.medscape.com Author: staff Social support and psychologic/psychiatric interventions can improve survival in cancer but are &#8220;overlooked&#8221; in the treatment of the disease, argues a psychiatrist in an essay published in the February 2 issue of the Journal of the American Medical Association. &#8220;A patient&#8217;s personal mental management of the stresses associated with cancer&#8221; is [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/in-cancer-survival-mind-matters-says-expert/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Rash prediction in lung cancer?</title>
		<link>http://oralcancernews.org/wp/rash-prediction-in-lung-cancer/</link>
		<comments>http://oralcancernews.org/wp/rash-prediction-in-lung-cancer/#comments</comments>
		<pubDate>Wed, 26 Jan 2011 15:09:24 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[biomarker]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[rash]]></category>
		<category><![CDATA[survival]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=10317</guid>
		<description><![CDATA[Source: www.medscape.com Author: Maurie Markman, MD Hello. I am Dr. Maurie Markman from Cancer Treatment Centers of America in Philadelphia. I wanted to briefly discuss with you a very interesting paper[1] that appeared online in The Lancet Oncology on December 20th, 2010, and will be in print soon. The paper was entitled &#8220;First-Cycle Rash and [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/rash-prediction-in-lung-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Three-drug combination shows long-lasting survival benefit in head and neck cancer patients</title>
		<link>http://oralcancernews.org/wp/three-drug-combination-shows-long-lasting-survival-benefit-in-head-and-neck-cancer-patients/</link>
		<comments>http://oralcancernews.org/wp/three-drug-combination-shows-long-lasting-survival-benefit-in-head-and-neck-cancer-patients/#comments</comments>
		<pubDate>Fri, 14 Jan 2011 00:08:13 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[cisplatin]]></category>
		<category><![CDATA[docetaxel]]></category>
		<category><![CDATA[fluorouracil]]></category>
		<category><![CDATA[induction therapy]]></category>
		<category><![CDATA[radiotherapy]]></category>
		<category><![CDATA[survival]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=10243</guid>
		<description><![CDATA[Source: www.medicalnewstoday.com Author: staff Adding a third drug (docetaxel) to a standard two-drug initial chemotherapy regimen significantly improves the long-term survival of patients with head and neck cancer, reducing the likelihood of dying by 26% over 6 years. The long-term results of the TAX 324 trial published Online First in The Lancet Oncology, confirm that [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/three-drug-combination-shows-long-lasting-survival-benefit-in-head-and-neck-cancer-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>PMI Labs lowers price of oral cancer brush biopsy test</title>
		<link>http://oralcancernews.org/wp/pmi-labs-lowered-price-of-oral-cancer-early-detection-test/</link>
		<comments>http://oralcancernews.org/wp/pmi-labs-lowered-price-of-oral-cancer-early-detection-test/#comments</comments>
		<pubDate>Sat, 23 Oct 2010 18:10:29 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[biopsy]]></category>
		<category><![CDATA[cyto-brush]]></category>
		<category><![CDATA[detection test]]></category>
		<category><![CDATA[DNA abnormality]]></category>
		<category><![CDATA[early stage]]></category>
		<category><![CDATA[lesions]]></category>
		<category><![CDATA[OralAdvance]]></category>
		<category><![CDATA[survival]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=9646</guid>
		<description><![CDATA[Source: www.marketwire.com/ Author: press release PMI Labs is excited to announce that the price of OralAdvance™, the Company&#8217;s innovative test designed to detect early stage oral cancer, is lowered by 35% as a result of the completion of the next generation quantitative cytology analysis platform, ClearCyte™. The redesigned and reengineered ClearCyte™ platform allows for faster [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/pmi-labs-lowered-price-of-oral-cancer-early-detection-test/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Lilly presents new data in head and neck cancer &#8211; a difficult to treat cancer with poor survival rates</title>
		<link>http://oralcancernews.org/wp/lilly-presents-new-data-in-head-and-neck-cancer-a-difficult-to-treat-cancer-with-poor-survival-rates/</link>
		<comments>http://oralcancernews.org/wp/lilly-presents-new-data-in-head-and-neck-cancer-a-difficult-to-treat-cancer-with-poor-survival-rates/#comments</comments>
		<pubDate>Wed, 13 Oct 2010 21:39:16 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[alimta]]></category>
		<category><![CDATA[cisplatin]]></category>
		<category><![CDATA[pemetrexed]]></category>
		<category><![CDATA[survival]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=9577</guid>
		<description><![CDATA[Source: www.prnewswire.com Author: press release Eli Lilly and Company announced today that its global Phase III trial evaluating Alimta® (pemetrexed for injection) in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (SCCHN) did not meet its primary endpoint for overall survival. Data were presented for the [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/lilly-presents-new-data-in-head-and-neck-cancer-a-difficult-to-treat-cancer-with-poor-survival-rates/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ASCO: Second study links HPV to mouth cancer outcomes</title>
		<link>http://oralcancernews.org/wp/asco-second-study-links-hpv-to-mouth-cancer-outcomes/</link>
		<comments>http://oralcancernews.org/wp/asco-second-study-links-hpv-to-mouth-cancer-outcomes/#comments</comments>
		<pubDate>Mon, 07 Jun 2010 21:51:28 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[OCF In The News]]></category>
		<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[cisplatin]]></category>
		<category><![CDATA[HPV]]></category>
		<category><![CDATA[HPV positive]]></category>
		<category><![CDATA[human papillomavirus]]></category>
		<category><![CDATA[radiotherapy]]></category>
		<category><![CDATA[smoking]]></category>
		<category><![CDATA[survival]]></category>
		<category><![CDATA[tobacco]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=8819</guid>
		<description><![CDATA[Source: www.medpagetoday.com/ Author: Michael Smith, North American Correspondent, MedPage Today Human papillomavirus (HPV) infection predicts a better chance of survival in patients with oropharyngeal squamous cell carcinoma, researchers said. In a retrospective analysis of a major radiation therapy trial, more than four-fifths of patients whose tumors were HPV-positive were alive three years after treatment, according [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/asco-second-study-links-hpv-to-mouth-cancer-outcomes/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>No need to fear!</title>
		<link>http://oralcancernews.org/wp/no-need-to-fear/</link>
		<comments>http://oralcancernews.org/wp/no-need-to-fear/#comments</comments>
		<pubDate>Mon, 31 May 2010 13:26:42 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[calming technology]]></category>
		<category><![CDATA[Cranial Electrotherapy Stimulation]]></category>
		<category><![CDATA[dental phobias]]></category>
		<category><![CDATA[dopamine]]></category>
		<category><![CDATA[NuCalm]]></category>
		<category><![CDATA[serotonin]]></category>
		<category><![CDATA[survival]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=8768</guid>
		<description><![CDATA[Source: www.healthcanal.com Author: staff Patients with dental phobias will now be able to relax in the dentist’s chair, as new brain calming technology can help de–stress those with even the worst fears. New equipment developed by neuroscientists in America is being introduced in dental surgeries in the UK to help calm patients who suffer anxiety [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/no-need-to-fear/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Enzyme predictive of head and neck cancer survival</title>
		<link>http://oralcancernews.org/wp/enzyme-predictive-of-head-and-neck-cancer-survival/</link>
		<comments>http://oralcancernews.org/wp/enzyme-predictive-of-head-and-neck-cancer-survival/#comments</comments>
		<pubDate>Tue, 20 Apr 2010 19:16:16 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[enzyme]]></category>
		<category><![CDATA[ERCC1]]></category>
		<category><![CDATA[survival]]></category>
		<category><![CDATA[tissue samples]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=8441</guid>
		<description><![CDATA[Source: www.insidermedicine.ca Author: staff Scientists have identified an enzyme that may predict survival from head and neck cancer, according to a report presented at the annual meeting of the American Association for Cancer Research. Researchers analyzed tissue samples from over 100 squamous carcinoma patients, finding that those with low levels of the enzyme ERCC1 had [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/enzyme-predictive-of-head-and-neck-cancer-survival/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
<enclosure url="http://oralcancernews.org/wp/wp-content/uploads/2010/04/enzyme02.mov" length="642342" type="video/quicktime" />
		</item>
	</channel>
</rss>

